CLINICAL TRIALS PROFILE FOR BLD-2660
✉ Email this page to a colleague
Clinical Trials for BLD-2660
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03559166 ↗ | First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis | Completed | Blade Therapeutics | Phase 1 | First in Human single ascending dose followed by multiple ascending doses in healthy volunteers. |
| NCT04001998 ↗ | Healthy Volunteer Study Comparing Tablet and Capsule Formulations | Withdrawn | Blade Therapeutics | Phase 1 | Single center, randomized, open label, two-part crossover study designed to evaluate the PK, food effect, dose proportionality, safety, and tolerability of BLD-2660 in healthy volunteers. |
| NCT04244825 ↗ | Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF | Withdrawn | Blade Therapeutics | Phase 2 | A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis |
| NCT04334460 ↗ | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | Active, not recruiting | Clinipace Worldwide | Phase 2 | BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP) inhibition. It is under development for the treatment of coronavirus disease-19 (COVID-19) resulting from infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2), where there is significant unmet medical need. |
| NCT04334460 ↗ | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | Active, not recruiting | Blade Therapeutics | Phase 2 | BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP) inhibition. It is under development for the treatment of coronavirus disease-19 (COVID-19) resulting from infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2), where there is significant unmet medical need. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for BLD-2660
Condition Name
Clinical Trial Locations for BLD-2660
Trials by Country
Clinical Trial Progress for BLD-2660
Clinical Trial Phase
Clinical Trial Sponsors for BLD-2660
Sponsor Name
